JBS-003 will be evaluated in an ongoing phase 3 trial designed to determine whether investigators can identify patients who can safely receive less radiation.
|Videos|June 19, 2017
Dr. Machiels on Toxicities with Pembrolizumab for Head and Neck Cancer
Author(s)Jean-Pascal Machiels, MD
Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses toxicities with pembrolizumab (Keytruda) in combination with chemoradiation for patients with head and neck cancer.
Advertisement
Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses toxicities with pembrolizumab (Keytruda) in combination with chemoradiation for patients with head and neck cancer.
The main adverse event to expect when treating a patient with pembrolizumab for head and neck cancer are endocrine side effects. However, it is also important to be aware of possible serious adverse events such as colitis or liver toxicities, states Machiels.
Advertisement
Related to this article
Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026
5